ChoA Pharmaceutical Co Ltd
KOSDAQ:034940
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
889
1 269
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| KR |
C
|
ChoA Pharmaceutical Co Ltd
KOSDAQ:034940
|
27.9B KRW |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
528.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
275.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.3B GBP |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
221.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
267.9B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.6B USD |
Loading...
|
Market Distribution
| Min | -163 055.6% |
| 30th Percentile | -2.2% |
| Median | 2.7% |
| 70th Percentile | 6.8% |
| Max | 22 874.8% |
Other Profitability Ratios
ChoA Pharmaceutical Co Ltd
Glance View
ChoA Pharmaceutical Co., Ltd. engages in the manufacture and sale of medicine and health supplement food. The company is headquartered in Seoul, Seoul. The Company’s products are mainly for treatment of indigestion, gastric ulcer, duodenal ulcer, gastritis, gastric hyperacidity, intestinal disorder, constipation, diarrhea, stomachache, calcium deficiency, fatigue, iron deficiency anemia, neurasthenia, hypertension, hyperlipidemia, circulatory disorder, medicine poisoning, hepatic disease, allergic rhinitis, cough, cold, rheumatoid arthritis and others. The company also provides nutrition products, health drinks, mixed drinks, beverages for children, cosmetics and others.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for ChoA Pharmaceutical Co Ltd is -14.2%, which is below its 3-year median of -10%.
Over the last 3 years, ChoA Pharmaceutical Co Ltd’s Operating Margin has decreased from -6.1% to -14.2%. During this period, it reached a low of -16.3% on Mar 31, 2025 and a high of 1% on Jun 30, 2023.